Breaking News: Expected Passage of 2018 Farm Bill on Monday Could Provide Opportunity to Gain Big in this Uncertain Market
December 07 2018 - 8:30AM
Cannagreed.com News Commentary
While stocks have taken a beating due to trade concerns with
China and rising rates, there is green at the end of the tunnel!
With the expected vote and passage of the 2018 Farm Bill on Monday,
stocks that are in the CBD space are poised to benefit and should
run counter to the current market downward trends. Stocks in the
CBD and cannabis space have not been immune from the market’s
downturn, but the expected passage of the bill should provide an
opportunity to acquire high growth stocks in this bear market.
Cannabidiol, or CBD, is the non-psychoactive chemical compound
found in the hemp plant. The 2018 Farm Bill will nationally
legalize the cultivation and farming of that plant. It is also
expected that the passage of the bill will allow for the national
legalization of CBD, lifting many barriers that exist for full
scale commercial acceptance of the compound. Brightfield
Group, a company that specializes in cannabis and CBD market
research, projects that the medical and recreational CBD market is
expected to reach an estimated value of $22 billion by 2022.
Many companies have been positioning themselves to take
advantage of this huge, untapped market opportunity that the CBD
and Hemp space presents. These companies present an opportunity to
get in early and capitalize from expected passage of the Farm Bill
before it could be too late;
GW Pharmaceuticals (OTC: GWPRF), the maker of Epidiolex, an
epilepsy drug that contains CBD. This is the first FDA-approved
drug made from the cannabis plant, and its approval was done in
tandem with the FDA reclassifying certain drugs containing CBD to
Schedule 5 drugs. The Company is more than 33% off its
52-week high of $15.00; Tiprank recently gave the Company a price
target of $190. This Company presents a good opportunity for
a bio-pharma CBD play.
CV Sciences (OTC: CVSI), the U.S.-based company whose primary
product is a chewing gum that combines CBD with nicotine, used in
the treatment of tobacco addiction. CSVI’s therapy product has
significant upside for the CBD and Hemp industry. The medical
community has reacted very positively to the Company’s recent
developments. CSVI posted over a 100% increase in revenue gain from
2016 to 2017 fiscal years, and surpassed its 2017 sales figure
through the first 6 months of fiscal 2018. The Company is trading
50% lower than its 52-week average; CBD legalization should send it
back towards its 52-week highs.
Aurora Cannabis (NYSE: ACB), the first cannabis stock to be
listed on the New York Stock Exchange (NYSE), announced that Aurora
launched its line of CBD Soft gel capsules, a product that has
enormous opportunity in the over the counter medical market. Based
on the Company’s projections, this product line has the opportunity
to generate over $100 million in annual sales. This new product is
in addition to the Company’s core cannabis production and
distribution business. The Company is 60% off its 52-week highs, so
there is a lot of potential to capture upside in this stock.
Cannabis Sativa, Inc. (OTC: CBDS), is a US based marketer and
manufacturer of cannabis & hemp products. The Company recently
announced that it had secured a patent for a CBD lozenge that helps
treat hypertension. This opens up a potentially huge medical
opportunity for the Company, as hypertension is the one of the
country’s biggest ailments, afflicting over 90 million people. The
Company is currently over 66% off its 52-week high, and is poised
for large gains upon passage.
American Premium Water Corporation (OTC: HIPH), the marketer and
distributor of LALPINA CBD, the first hydro-nano beverage on the
market, announced that it has formed a distribution partnership
with Upside Health’s product Ouchie, a pain management app and
platform targeting the over 120 million Americans who live with
chronic pain. This partnership will give the Company access to a
captive audience of consumers afflicted with pain who are most
likely to benefit from CBD products. The Company is trading at 80%
its 52-week lows, and was recently given a price target of
$0.30.
For commentary inquiries, please contact:
info@cannagreed.com
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words
such as "may", "future", "plan" or "planned", "will" or "should",
"expected," "anticipates", "draft", "eventually" or "projected".
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company's annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and CG undertakes no
obligation to update such statements.
You should not rely on the information presented; you should do
independent research to form your own opinion and decision.
Information contained in our disseminated emails does not
constitute investment, legal or tax advice upon which you should
rely. The purchase of high-risk securities may result in the loss
of your entire investment. Advertisements received by you are not a
solicitation or recommendation to buy securities of the advertised
company. CG was not compensated by (NYSE: ACB), (OTCPK: CBDS),(OTC:
HIPH), (OTCQB: GWPRF), (OTC: CVSI) or any other company
mentioned in this article.
Full Disclaimer: http://www.cannagreed.com/disclaimer/
Contact Information: www.CannaGreed.com
info@cannagreed.com SOURCE: Cannagreed
Aurora Cannabis (NASDAQ:ACB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aurora Cannabis (NASDAQ:ACB)
Historical Stock Chart
From Sep 2023 to Sep 2024